Atlas Trials

Phase III Clinical Trial of Telitacicept Injection in the Treatment of Patients With Connective Tissue Disease-related Interstitial Lung Disease

Clinical trial NCT07495033 · NOT_YET_RECRUITING

Trial details

NCT number
NCT07495033
Sponsor
RemeGen Co., Ltd.
Status
NOT_YET_RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
CTD-ILD
Start date
2026-04-20
Primary completion
2029-05-31
Enrollment
260

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.